By Fineline Cube 
Johnson & Johnson (J&J) (J&J, NYSE: JNJ) announced second-quarter 2026 results, reporting sales growth of 6.6% year-over-year (YOY) to USD 25.3 billion. The company’s strong operational performance has prompted an increase in its full-year 2026 guidance, with estimated reported sales now projected at USD 101.1 billion (7.3% growth at the midpoint).
Financial Performance | Q2 2026 Highlights
| Metric | Q2 2026 | YOY Change |
|---|---|---|
| Total Sales | USD 25.3B | +6.6% |
| US Sales | USD 14.5B | +7.3% |
| International Sales | USD 10.8B | +5.7% |
| Revised FY2026 Guidance | USD 101.1B | +7.3% (midpoint) |
Business Segment Performance
Innovative Medicine
- Worldwide Operational Sales: USD 16.4 billion (+6.8% YOY)
- Key Growth Drivers:
- Oncology: DARZALEX (USD 4.2B, +18.9%), CARVYKTI (USD 657M, +49.4%), TECVAYLI (USD 260M, +56.5%), RYBREVANT/LAZCLUZE (USD 289M, +60.8%)
- Immunology: TREMFYA (USD 2.0B, +72.5%)
- Neuroscience: SPRAVATO (USD 584M, +40.8%), CAPLYTA (USD 361M, +70.9%)
- Partial Offsets: STELARA and REMICADE (Immunology); IMBRUVICA and ZYTIGA (Oncology)
MedTech
- Worldwide Operational Sales: USD 8.9 billion (+3.6% YOY)
- Key Growth Drivers:
- Surgery: Wound closure products and biosurgery products
- Cardiovascular: Electrophysiology products and Shockwave
- Vision: Contact lenses
- Orthopaedics: Trauma products
Regional Performance
The US market remained J&J’s largest revenue contributor with USD 14.5 billion in sales, representing a 7.3% YOY increase. International markets delivered USD 10.8 billion in sales, up 5.7% YOY, demonstrating balanced global growth across both developed and emerging markets.
Strategic Outlook
J&J’s raised guidance reflects confidence in its diversified portfolio and innovation pipeline. The company continues to benefit from strong momentum in its high-growth therapeutic areas, particularly in oncology and immunology, where newer products are offsetting expected declines in legacy franchises.
The robust performance of cell therapy assets like CARVYKTI (+49.4%) and bispecific antibodies such as TECVAYLI (+56.5%) and RYBREVANT/LAZCLUZE (+60.8%) underscores J&J’s successful strategic pivot toward next-generation oncology treatments.
In MedTech, steady growth across multiple categories demonstrates the resilience of J&J’s medical device portfolio despite ongoing supply chain normalization and post-pandemic market adjustments.
Forward-Looking Statements
This brief contains forward-looking statements regarding financial performance, product sales, and business outlook. Actual results may differ materially due to risks including regulatory changes, competitive pressures, market dynamics, and global economic conditions.-Fineline Info & Tech